Trial Profile
A phase IIb, randomized, multicenter, noncomparative pilot study of the safety and efficacy of three docetaxel-based chemotherapy regimens plus bevacizumab +/- trastuzumab for the adjuvant treatment of patients with node-positive and high-risk node-negative breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Ductal carcinoma
- Focus Adverse reactions
- Sponsors Sanofi
- 24 Jan 2012 Actual patient number 121 added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.